{"name":"Shanghai YingLi Pharmaceutical Co. Ltd.","slug":"shanghai-yingli-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AK-1286","genericName":"AK-1286","slug":"ak-1286","indication":"Other","status":"phase_1"},{"name":"YL-17231","genericName":"YL-17231","slug":"yl-17231","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AK-1286","genericName":"AK-1286","slug":"ak-1286","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"YL-17231","genericName":"YL-17231","slug":"yl-17231","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPLVBJeFZJZml5ekJDN2c5WVZScTlYV0hlelcwdzQxMlhVMkoxcTd1aVRYUzA0cXpRbHptXzd3QVl1UWxDYUVNVmZtR203azJwOF9wNE43YlFyc3F2RjhDZ1l2dlJzZzJrWWRCM0M1a1pYSTdxUTkwdDJfcUNFRERYS1FBMzZRNlEtZGZLU3ozTk1PV25jSGNJ?oc=5","date":"2026-03-11","type":"pipeline","source":"openPR.com","summary":"Peripheral T-Cell Lymphoma Market Outlook 2034: US Market - openPR.com","headline":"Peripheral T-Cell Lymphoma Market Outlook 2034: US Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE4xMHVKU1RITHdrZjVaUW1md05BUnU3UzhLMG82YXJHUWtDYnpMTDFEU051UjVWVlFDLTcyb3dpQTZQcTVnempQbmM0ekhjeVBPVlp2NDJyMHl1QllIR3ZF?oc=5","date":"2026-01-13","type":"trial","source":"Nature","summary":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson - Nature","headline":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPRVd6WXpfckdJZGoxTUJaOGRyaXpqcXgzX1RSS0xmRFp6MEx5NUJqQkZfaW5rQTRSMDBJWG9mZ2ZnQUMtZl9WTkhoNFdiZ1hyekYxUXczTzhhZlZtd1ZsSWg0d2plTnZPU3pUY0xsR0g0MnQ2OGUtcXdzOExuaEhJdDNoMGRLZ0owUzZ0WHFweHZRZnlrODBud0htTzUwcndEb1A2QzdQb3dOTFBMSGM3MmJCZEVmZmthNmdibmN6MnBNYmtFLTdNSzl3X2FZSmUyN3lNemFaQ1JmNnI2dU9ZLWVMSFgyQXlzU0thSGl3ZWpDbklKbjlpelA4WEFhQTlxMzIyYlB3cHRGNWhDRnVmb0Z0NlVOSnFSU3B0Zzh0eFgtbWlGTEtlMURhNjFUd3dFMEow?oc=5","date":"2025-07-21","type":"pipeline","source":"GlobeNewswire","summary":"Cutaneous T-cell Lymphoma Market Anticipates Impressive - GlobeNewswire","headline":"Cutaneous T-cell Lymphoma Market Anticipates Impressive","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNVmxTVFJBV3RLNGJPVkQzTVFZYjNUSU9wYk1PMHlRVkU0TnNITDRBa1BJUlFEZ1dZeHUyNmRhTG1YRWUwb3dMSE9UWHFOX0E2bEgwREVacHJPWlg0bk1IYzdXVWwxMHpMMEJoN3o0U3JHS0UyNklmTS0zYTJsRXVvMmF1SU5nRkFHaXR4bGhjS2pRellDenAyUXZYa1dwbG9Q?oc=5","date":"2025-04-03","type":"regulatory","source":"Targeted Oncology","summary":"FDA OKs Phase 3 Study of Linperlisib in Peripheral T-Cell Lymphoma - Targeted Oncology","headline":"FDA OKs Phase 3 Study of Linperlisib in Peripheral T-Cell Lymphoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE5QT0JZU0kzaU5qTUZSaGtuTXZsMVFaN3d6NVpJREdBeTEwUXZPOUh2UDV0YTJqZmlFUXNfNFNrTWQydjJ0Z205VXlPdkxrV2lFYXl1U2hHUXpHY2tCS1FfaEt2aG9wVmF4RmNTNGFrOGlhcFJrTmc?oc=5","date":"2025-04-02","type":"regulatory","source":"Clinical Trials Arena","summary":"Yingli Pharma gains FDA approval for Phase III trial of r/r PTCL drug candidate - Clinical Trials Arena","headline":"Yingli Pharma gains FDA approval for Phase III trial of r/r PTCL drug candidate","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2025-03-27","type":"pipeline","source":"prnewswire.com","summary":"The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Di","headline":"The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal ant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPeV8yRUQtTXk3dWdxby15MmpPeDFXVnNMa0QxaFg5Wlo1S29xU0xLSnZuNHhxcjVsZ2FjY0Q5SlUxM0Y1cXdZYVJWUTh3WTZZNmhaMDNIWXVGMllnRzg5b2dId1I4YnY3WmlUUTNxOEpST3cteDYzNXd2endNdUVNb3ZBNkxwUjAtV3NRblc4aHg5TG5QdXdMYWl4dElJQWs5WDVzTw?oc=5","date":"2024-08-22","type":"pipeline","source":"BioWorld News","summary":"Shanghai Kygent Pharmaceutical describes new DNMT1 inhibitors - BioWorld News","headline":"Shanghai Kygent Pharmaceutical describes new DNMT1 inhibitors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQOG5sZEpjUzZkYzhvUUl0YVh3QjFuTVdsREQ0SnB0X0trN0NEbmw0Z2ZnZ296dWhQalE1OFNIdHZGYUZ2Q0lIQTQxUElFNWlnbU11dFJWcVQ5Wk12ZWpQaGJyVUZSWnB4NFA0ZXR3TXNIZVNXTFNGb0MtMEl2OC1BaE1NV2xKVnhHM0xJYmpnNVZ5eWUxbDlFczdDaGR3RGV2QlQ0THZkM0RuZ29qZW1kMjcyVGI?oc=5","date":"2024-04-12","type":"pipeline","source":"seekingalpha.com","summary":"Revolution Medicines: An Expensive Shot At A Massive Market Opportunity (NASDAQ:RVMD) - seekingalpha.com","headline":"Revolution Medicines: An Expensive Shot At A Massive Market Opportunity (NASDAQ:RVMD)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxONHJsVHR6aGJNbzdkUmFaVEpBNDZFQmlVeElxMVk0QUNXY3RDNUtka2xvaE1JOFVXV0JuWU94YzBQNEJoam5YLWJlZlBKWVFaXzh5VlYzaWJEZWpBRWZ3c0pHQVU0eGFjcFRkeEgxZ1d6bHhRdGhJdUdIV3dvUF95ekl5ejVrNk9uVmlVMXlB?oc=5","date":"2024-03-21","type":"trial","source":"Yahoo Finance","summary":"PI3K Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 75+ Companies Working in the Domain - Yahoo Finance","headline":"PI3K Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 75+ C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE40OUgwR0tfZjNlN3BOZFZsOFRkSW9MeUx4YjEtc3VHZDRHWnYzUmU1NElCQjhvUmFocEdUOThTc1M3UklYdjNXb1VRZWVkNlF2UGJHT1k0eXRSU2F1WHRNbE45VUZRb0NnNnVCcEstdjdoVzhQWWNiTnVB?oc=5","date":"2017-09-04","type":"pipeline","source":"Dignity Memorial","summary":"Min Zhou Obituary - Raleigh, NC - Dignity Memorial","headline":"Min Zhou Obituary - Raleigh, NC","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}